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                                                       ABSTRACT 
INTRODUCTION: 
               Several endocrinopathies have been reported to be associated with HIV 
infection when the CD4 count is low. So before the advent of HAART, subclinical 
and clinical thyroid, adrenal and gonadal disturbances have been identified1. 
An abnormal thyroid function test results are seen among human 
immunodeficiency virus (HIV) infected patients and is caused by various 
mechanisms such as infiltration of the gland by opportunistic infections or a 
systemic manifestation of the infection itself. This causes subclinical 
Hypothyroidism4 which is a precursor to overt hypothyroidism. 
                 Subclinical hypothyroidism is associated with only mild clinical 
abnormalities and is characterised by normal T4 values but with elevation in 
thyroid-stimulating hormone (TSH).Specific thyroid function test abnormalities are 
identified among HIV-infected patients. But the incidence of overt thyroid illness 
is same as that of the general populationAmong the HIV patients: 
Overt thyroid disease 1-2% 
Subtle abnormalities in thyroid function test 5, 6, and 7 35% 
Thyroid abnormalities in HIV-infected patients are dealt in detail in this study. 
 
 
AIMS AND OBJECTIVES OF THE STUDY: 
                To evaluate patients with human immunodeficiency virus (HIV) 
infection for the prevalence of thyroid dysfunction and to correlate the results with 
the CD4 count. 
MATERIALS AND METHODS: 
STUDY POPULATION: 
                This study is to be conducted among 50 patients with Seropositive HIV, 
attending the Department of Medicine & ART Centre in Govt. Rajaji Hospital, 
Madurai. 
STUDY PROTOCOL: 
               In Patients of HIV Positive on ART, both sex, T3, T4, TSH, CD4 Count 
are done .Results are then analysed 
RESULTS: 
               People with CD4 count between 100- 200 were having a mean TSH value 
of 8.45+/-0.32 and people with CD4 less than <100 were having TSH values 
9.75+/-0.39 (p= <.001) and there is no significant correlation between thyroid 
dysfunction and patients on HAART 
 
 
 
CONCLUSIONS: 
            Thyroid dysfunction is found in significant association with HIV infection 
and a hypothyroid state occurs in HIV infection as the disease progresses. Males 
and females suffering from HIV show equal incidence of thyroid dysfunction. 
All individuals with CD4 count less than 200 should be screened for 
hypothyroidism. In individuals with a low CD4 count, a lower BMI is observed as 
compared to other patients with CD4 counts higher than them. There is no 
significant correlation between thyroid dysfunction and patients treated with 
HAART. 
KEY WORDS: Thyroid dysfunction, Thyroid function test, HIV, HAART, CD4 
Count, 
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INTRODUCTION 
 
Several endocrinopathies have been reported to be associated with HIV 
infection when the CD4 count is low. So before the advent of HAART, 
subclinical and clinical thyroid, adrenal and gonadal disturbances have been 
identified1. 
An abnormal thyroid function test results are seen among human 
immunodeficiency virus (HIV) infected patients and is caused by various 
mechanisms such as infiltration of the gland by opportunistic infections or a 
systemic manifestation of the infection itself. This causes subclinical 
Hypothyroidism4 which is a precursor to overt hypothyroidism. 
Subclinical hypothyroidism is associated with only mild clinical 
abnormalities and is characterised by normal T4 values but with elevation in 
thyroid-stimulating hormone (TSH). 
Euthyroid sick syndrome (i.e. non thyroidal illness) is more common in 
HIV patients with advanced disease. Specific thyroid function test 
abnormalities are identified among HIV-infected patients. But the incidence of 
overt thyroid illness is same as that of the general population. During HAART 
therapy, many patients screened had an elevated thyroid-stimulating hormone 
levels and decreased free thyroxin levels. 
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In immune reconstitution syndrome the exact opposite occurs. It is 
characterised by Graves’ disease with low TSH and increased thyroxin levels. 
Routine thyroid screening of asymptomatic HIV infected individuals is not 
recommended. But testing of symptomatic patients should begin with 
measurement of the TSH level. 
This review highlights the current evidence regarding the optimal 
evaluation of thyroid function test and discusses the controversies of routine 
screening. 
Among the HIV patients: 
Overt thyroid disease 1-2% 
Subtle abnormalities in thyroid function test 5, 6, and 7 35% 
The physician must interpret abnormal thyroid function test with the 
above results in mind. The diagnosis, treatment and interpretation of thyroid 
function tests in HIV-infected patients are reviewed and the indications for 
screening are formulated. Current concepts in thyroid dysfunction in HIV 
patients, in contrast to the general population with a broader context for 
thyroid abnormalities in HIV-infected patients are dealt in detail in this study. 
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AIMS AND OBJECTIVES OF THE STUDY 
 
 To evaluate patients with human immunodeficiency virus (HIV) 
infection for the prevalence of thyroid dysfunction. 
 To correlate the results with the CD4 count 
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REVIEW OF LITERATURE 
 
HISTORY: 
Hypothyroidism is a clinical syndrome which was described for the first 
time in London in 1870. It was named myxedema. In 1888 it was accepted 
widely that cretinism myxedema and post thyroidectomy changes were a result 
of loss of function of thyroid body. Kendall isolated thyroxin for the first time 
in 1914. Harrington synthesized it for the first time in 1926.However; 
synthesis of thyroxin was done in large scale in 1949. Later it became a 
universally accepted therapy for hypothyroidism8 
 
THYROID GLAND: 
Anatomy of Thyroid: 
Thyroid gland comprises of: 
 A midline isthmus lying horizontally just below the cricoid  cartilage 
 Right and left, two lateral lobes that extend superiorly together, in 
front of neck giving the appearance of a butterfly shape. 
 The gland is fully enclosed by pre tracheal fascia, under the strap 
muscle, which makes the gland move up with deglutition25. 
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Histology of thyroid: 
 Thyroid gland is divided by Thin fibrous septa into pseuolobules 
 These pseudolobules are composed of vesicles otherwise called follicles 
or acini, are densely surrounded by a capillary network. 
 Follicular walls are surrounded by cuboidal epithelium 
 Proteinaceous colloidal material is filled within the lumen of follicles 
which contains the unique protein called thyroglobulin. The peptide 
sequences of T4 and T3 are stored and synthesized as a component of 
thyroglobulin. 
 
Development of thyroid: 

 Develops from the ectoderm of the floor of the pharynx with some 
contribution from the lateral pharyngeal pouches. 

 The thyroglossal duct, which extends from the foramen caecum near the 
base of the tongue to the isthmus of the thyroid arise from descent of 
the midline thyroid anlagen. 

 The posterior aspect of the thyroid gland becomes associated with the 
parathyroid gland and the para follicular C cells, during the 
development, which are derived from ultimo-bronchial body, which 
become incorporated in to its substance25. 

 While they undergo malignant transformation, the C cells are the source 
of the calcitonin and gives rise to medullary thyroid carcinoma. 
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
 At about 10-12 weeks of intra uterine life, the foetal thyroid begins to 
concentrate and organify iodine. 

 Maternal TSH and T4 do not cross the placenta, but the maternal TRH 
crosses the placenta. 

 The major source of thyroid hormone in the foetal life is T4 from the 
foetal thyroid. 

 The functional unit is foetal pituitary- thyroid axis which is distinct 
from that of mother. 
 
PHYSIOLOGY OF THYROID GLAND: 
Thyroid secretes three hormones – thyroxin (T4), triiodothyronine (T3) 
and calcitonin.  Thyroid follicles secrete the first two hormones, have similar 
biological activity and the term “thyroid hormones” is pertinent to these 2 
hormones only. Calcitonin is chemically and biologically different entirely and 
is secreted from parafollicular C cells. It regulates calcium metabolism and it is 
considered along with parathormone. 
Thyroid hormone contains iodine. Iodine enters the thyroid in the form 
of inorganic or organic iodide is oxidized by a peroxidase enzyme at the cell- 
colloidal interface. Subsequent reactions results in formation of thyroxin.  The 
only source of T4 is thyroid gland. Thyroid secretes 20% of T3; extra 
glandular tissues produce the remaining amount by the peripheral conversion 
of T4 into T325. 
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CHEMISTRY AND SYNTHESIS OF THYROID HORMONE: 
Both T4 and T3, which is a condensation product of 2 molecules of 
tyrosine are iodine containing derivatives of thyronine. 
Thyroxine (T4)        -   3, 5, 3’, 5’- tetraiodothyronine 
T3          -   3, 5, 3’ – triiodothyronine 
      Thyroid hormones are synthesized and stored in thyroid follicles as part 
of thyroglobulin molecule which is a glycoprotein synthesized in thyroid cells, 
contains 10% of sugar, MW 660 KDa.  There are 5 steps in synthesis of 
thyroid hormones. 
1. IODIDE UPTAKE OR IODIDE TRAPPING: Iodine from peripheral 
circulation is taken into the follicles by active transport process called 
 Na + I- symporter or NIS. Iodine content of follicle regulates the iodide 
trap. Meager storage activates and large storage inhibits this trap. This 
process    is mediated by TSH.  Percholarate, thiocyanates and nitrates 
inhibits this trapping. 
2. OXIDATION AND IODINATION :Iodide trapped by follicular cells is 
transported by one another transporter across the apical membrane called 
as “pendrin” and oxidized by thyroid peroxidase enzyme  present in 
follicular membrane and forms iodinium ions  (I+) or hypoiodous acid 
(HOI) or enzyme linked hypoiodate (E-OI) with the help of H2O2. 
These various forms of iodine bound avidly with thyroglobulin and 
forms monoiodotyrosine (MIT) and diiodotyrosine (DIT). 
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3. COUPLING: Pairs of iodinated tyrosine residues forms T3 and T4 by 
coupling with one another .Coupling belongs to oxidative reaction and is 
catalysed by the same thyroid peroxidase. Oxidation and coupling, both 
reactions are regulated by TSH. 
4. STORAGE AND RELEASE: Tyrosil residues are stored as thyroid 
colloid. These materials is taken back into follicular cells by endocytosis 
and undergo lysosomal proteolysis then released as T4 and T3. This 
colloidal uptake and proteolysis are mediated by TSH. At rest, follicles 
filled with colloid has flat or cuboidal epithelium and TSH stimulated 
follicles has columnar cells, colloid emptied. 
5. PERIPHERAL CONVERSION OF T4 TO T3: Conversion occurs 
predominantly in kidney and liver.  One third of T4 undergoes conversion 
and most of T3 in plasma is derived from liver. Target organs take up T3 
for metabolic functions except brain and pituitary which take up T4 and 
converts in to T3 by their own cellular mechanisms. 
 
Relation between T3 and T4: 
 Normally thyroid secretes more amount of T4 compared to T3. But 
this difference is reduced in iodine deficient state. 
 Normally T4 is the major circulating form because it is avidly bound 
with plasma proteins 15 times more. 
 T3 is five times more potent than T4. 
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 T3 acts very faster than T4. 
 Peak effect of T3 comes earlier (1-2 days), but peak effect of T4 
comes later (6-8 days). 
 T3 is more tightly bound to the nuclear receptors than T4 and the         
T4-receptor complex is not able to activate or depress the gene 
transcription. 
 About one third of T4 is converted in to T3 in peripheral tissues, in 
liver and kidney, by D1 type of 5’ Deiodinase (D1type 5’DI) and 
released in to circulation. But in addition, T3 is generated within the 
target cells like skeletal muscles, brain, pituitary and heart, by 
another enzyme type called type 2 deiodinase (D2 type 5’DI).  T4 is 
converted in to metabolically active T3 or inactive reverse T3 (r T3). 
 T4 and T3 metabolized in liver by conjugation with glucuronate and 
sulfate. Enzyme inducers such as phenobarbitone, carbamazepine and 
phenytoin increase the metabolic clearance of the hormones without 
decreasing the proportion of free hormones in the circulation. 
 Finally, T3 is an active form.  T4 is a transport form   i.e. precursor 
of T3. 
 Normal daily secretion of T3- 10-30 mcgm. T4- 60-90 mcgm. 
 T3 and T4 bound with 3 plasma proteins – they are 
i) Thyroxin binding globulin ( TBG ) 
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ii) Thyroxin binding pre albumin ( Transthyretin ) 
iii) Albumin 
 Plasma   t ½ of T3 is 1-2 days; of T4 is 6-7 days. The half life 
is increased in hypothyroidism and shortened in 
hyperthyroidism due to enhanced and blunted metabolism 
respectively. 
 Thyroid is the only source of T4. 
 
Circumstances with altered concentration of TBG25: 
INCREASED TBG    DECREASED TBG 
1. New born                         1. Phenytoin 
2. OCP / Estrogens/Tamoxifen    2.Acromegaly 
3. Biliary cirrhosis                        3.Androgens 
4. HAV/Chronic active hepatitis  4. Nephrotic syndrome 
5. Acute intermittent porphyria   5. Large doses of glucocorticoids  
       and Cushing’s syndrome 
6. Pregnancy                        6. Chronic liver disease 
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REGULATION OF SECRETION: 
Thyroid hormone secretion is regulated by hypothalamo-pituitary-
thyroid axis. Thyrotropin releasing hormone (TRH) from hypothalamus 
stimulates anterior pituitary to secrete TSH. This in turn stimulates thyroid 
gland and thyroxin is released from thyroid follicles. T3 and T4 are then 
released into circulation. T3 and T4 by the negative feedback mechanism 
directly control both hypothalamus and anterior pituitary. 
 
Thyrotropin releasing hormone: 
This is major positive regulator for pituitary TSH synthesis and release. 
TRH production starts infetus as early as 30 days of the gestation. It undergoes 
rapid degradation in the serum. It reaches pituitary by a pathway consisting of 
TRH fibres that enter median eminence and release TRH into portal system. 
TRH also reach pituitary by direct diffusion from hypothalamus or through 
cerebrospinal fluid and sub arachnoid process. 
 
The anterior pituitary: 
Anterior lobe contains multiple hormones cell type including cells that 
produce TSH.TSH cells are thought to be part of the lineage that is dependent 
on home box transcription factor pit-12. Fetal pituitary TSH synthesis can be 
detected by 13 weeks but remains low till 18 weeks after which both serum 
and pituitary TSH levels rise dramatically. This is followed by increase in the 
serum total and free T4 levels. 
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TSH Action: 
TSH regulates thyroid gland function through TSH-R, a seven-
transmembrane G protein–coupled receptor (GPCR). The TSH-R is coupled to 
the subunit of stimulatory G protein (G), activates adenylyl cyclase, leading to 
increased production of cyclic AMP. TSH also stimulates phosphatidylinositol 
turnover by activating phospholipase C. The functional role of TSH-R is 
exemplified by consequences of naturally occurring mutations. Recessive loss-
of-function mutations cause congenital hypothyroidism and thyroid 
hypoplasia. Dominant gain-of-function mutations cause sporadic or familial 
hyperthyroidism that is characterized by thyroid cell hyperplasia, goiter and 
autonomous function. 
This mimics the changes induced by TSH covalent binding or the 
interactions with thyroid-stimulating immunoglobulin’s (TSI) in Graves' 
disease. Activating TSH-R mutations occur as somatic events, leading to 
clonal selection and expansion of the affected thyroid follicular cell and 
autonomously functioning thyroid nodules. 
Although TSH is the dominant hormonal regulator of thyroid gland 
growth and function, many growth factors, secreted in the thyroid gland 
regulates the synthesis of thyroid hormone. They are endothelia, transforming 
growth factor (TGF),epidermal growth factor and insulin-like growth factor I 
(IGF-1). 
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The quantitative roles of these factors are not well understood, but they 
are important in selected disease states. In Acromegaly,  increased levels of 
growth hormone and IGF-1 are associated with goiter and predisposition to 
multinodular goiter (MNG).Certain interleukins (ILs) and cytokines produced 
in association with autoimmune thyroid disease induce thyroid growth, 
whereas others lead to apoptosis. Iodine deficiency upregulates the NIS. It 
increases blood flow to thyroid and iodine uptake. Transient inhibition of 
thyroid iodide organification, by excess iodide itself is called Wolff-Chaikoff 
effect. In individuals with normal thyroid,  iodide organification resumes and 
the gland escapes from this inhibitory effect; the suppressive action of high 
iodide may persist  in patients with underlying autoimmune thyroid disease10. 
 
CAUSES OF HYPOTHYROIDISM 
Primary: 
 Subtotal or total thyroidectomy, Iatrogenic treatment, external 
irradiation of neck for lymphoma. 
 Type 3 deoiodinase  over expression - infantile hemangioma 
 Congenital hypothyroidism: TSHR mutation, dyshormonogenesis, 
absent or ectopic thyroid gland 
 Infiltrative disorders like sarcoidosis, scleroderma, cystinosis, 
amyloidosis,  hemochromatosis,  Reidel’s thyroiditis 
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 Autoimmune hypothyroidism: atrophic thyroiditis, Hashimoto's 
thyroiditis. 
 Drugs: sunitinib, iodine excess (including iodine-containing contrast 
media and amiodarone),antithyroid drugs, interferon, cytokines, 
aminoglutethimide,lithium  andp-aminosalicylic acid, 
 Deficiency of iodine. 
 
Transient: 
 Withdrawal of thyroxine treatment 
 Post treatment or subtotal thyroidectomy for Graves' disease 
 Subacute thyroiditis 
 Silent thyroiditis, including postpartum thyroiditis. 
 
Secondary: 
 Hypothalamic disease:Infiltrative disorders, tumors, trauma, idiopathic 
 Hypopituitarism: tumors, pituitary surgery / irradiation, or infiltrative 
disorders 
 Isolated TSH inactivity or deficiency 
 Genetic forms of combined pituitary hormone deficiencies 
 Sheehan's syndrome, trauma 
 Bexarotene treatment. 
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CLINICAL PRESENTATION OF HYPOTHYROID DISORDERS: 
Symptoms: 
 Feeling cold 
 Dry skin 
 Tiredness, weakness 
 Hair loss 
 
Signs: 
 Puffy face, hands, and feet (my edema) 
 Constipation 
 Diffuse alopecia 
 Delayed tendon reflex relaxation 
 Weight gain with poor appetite 
 Dry coarse skin; cool peripheral extremities 
 Serous cavity effusions 
 Difficulty in concentrating and poor Memory 
 Dyspnoea 
 Peripheral edema 
 Bradycardia 
 Menorrhagia 
 Hoarse voice 
 Carpal tunnel syndrome 
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Clinical Examination: 
Examination is normal in most of the cases. However some may present 
with clinical signs such as typical hypothyroid facies suggestive of overt 
hypothyroidism. Skin maybe cold, dry, rough and scaly. Peripheral edema of 
feet and hand typically non pitting maybe seen. Nails maybe brittle and 
thickened. 
Some patients can have loss of hair in the lateral third of the eyebrows 
and scalp .Patients may have sinus bradycardia and diastolic hypertension. 
Blood pressure maybe normal or low in subclinical hypothyroidism. The 
thyroid gland may be rubbery, enlarged and firm. It is not tender and no bruit 
is heard. Thyroid maybe normal in size also. Patients can have memory loss 
and slow speech. A polyneuropathy or mononeuropathy like carpel tunnel 
syndrome with involvement of several peripheral nerves with complaints such 
as parasthesia may be seen in some cases. 
 
LABORATORY EVALUATION: 
Measurement of Thyroid Hormones: 
The TSH levels change dynamically in response to alterations of T4 and 
T3. The first approach to thyroid testing is to first find out whether TSH is 
normal, suppressed or elevated. With very rare exceptions, a normal TSH level 
excludes a primary abnormality of thyroid function. The enhanced sensitivity 
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and specificity of TSH assays have greatly improved laboratory assessment of 
thyroid function. 
Immune chemiilluminometric assays (ICMAs) for TSH are sensitive 
enough to discriminate between the suppressed values that occur with 
thyrotoxicosis and the lower limit of the reference range. Extremely sensitive 
(fourth-generation) assays can detect TSH levels 0.004 mU/L, but for practical 
purposes, assays sensitive to 0.1 mU/L are enough. The TRH stimulation test 
is now obsolete because of the widespread availability of the TSH ICMA. Also 
there is often a failure of TSH to rise after an intravenous bolus of 200–400 g . 
The finding of an abnormal TSH level should then be followed by 
circulating thyroid hormone levels to correctly diagnose hypothyroidism 
(elevated TSH) or hyperthyroidism (suppressed TSH). Radio immunoassays 
are widely available for serum totalT4 and total T3. T4 and T3 are highly 
protein-bound. Medications, illness, genetic factors etc. can influence protein 
binding.  So the free or unbound hormone levels, which correspond to the 
biologically available hormone pool should be measured next. 
This is because total thyroid hormone level is not affected by changes in 
serum binding protein affinity.  Serum TSH level is the first line investigation 
in the diagnosis of primary hypothyroidism and hyperthyroidism. However the 
test is not diagnostic in secondary thyroid dysfunction.  
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Thyroid hormones level in various clinical conditions25: 
 
CONDITION FREE T3 FREE  T4 TSH 
Subclinical hypothyroidism Increased Normal Normal 
Subclinical hyperthyroidism Normal Normal Low 
Primary hyperthyroidism Increased increased Undetectable 
Primary hypothyroidism Low or normal Low High 
Secondary hyperthyroidism 
(TSHoma) 
Increased Increased Normal /increased 
Secondary hypothyroidism Low or normal Low Low or normal 
T3 toxicosis Well increased normal undetectable 
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Drugs influencing metabolism and thyroid hormone function25: 
 
METABOLIC 
PROCESS 
INCREASED DECREASED 
Binding proteins Heroin, Estrogens, 
clofibrate 
Androgens,Glucocorticoids, 
phenytoin, Carbamazepine 
T4synthesis/ release Iodine Lithium, Iodide 
T4 / T3 binding in 
serum 
 Frusemide, Amiodarone, 
mefenamic acid, beta blockers, 
glucocorticoids, Salicylates 
T 4 metabolism Rifampicin 
Anticonvulsants 
 
TSH secretion Amiodarone Phenytoin, Glucocoticoids, 
dopamine agonists 
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THYROID HORMONE RESISTANCE25: 
This is a syndrome characterized by elevated free T3, free T4 but with 
normal TSH level. But TSH responsiveness to TRH is normal. Patient may 
have thyromegaly, short stature, attention deficit, mental retardation and 
learning difficulty and hyperactivity. The differential diagnosis for this is TSH-
secreting pituitary tumour. Treatment is by suppressing TSH with 
bromocriptine, D T4, tri iodo-thyroacetic acid and octreotide. Thyroid ablation 
by either radioiodine or surgery is tried if refractory to medical management. 
 
SCREENING FOR THYROID DISEASE23: 
The following patients should be screened for thyroid illness: 
1. Annual TFT  for diabetic patients 
2. Type 1 DM women in first trimester of pregnancy and post delivery 
3. Patients with hyperlipidaemia 
4. Monthly assessment in patients on amiodarone and lithium 
5. History of post partum thyroiditis 
6. Atrial fibrillation patients 
7. Annual TFT in Turner’ syndrome, Down’s syndrome, and Addison’s 
disease,because of high prevalence of hypothyroidism in those 
patients. 
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ATYPICAL THYROID FUNCTION TESTS25: 
TESTS CAUSE 
Detectable TSH , Elevated FT3,FT4 Heterophile antibodies 
TSH secreting pituitary tumour 
Thyroid hormone resistance 
Low FT3, Elevated FT4 Amiodarone 
Normal FT4, Suppressed TSH T3 toxicosis 
Suppressed TSH , Normal FT3,FT4 Excess thyroxine replacement 
Early subclinical thyrotoxicosis 
Sick euthyroidism 
Recovery from thyrotoxicosis 
 
SICK EUTHYROID SYNDROME/ NON THYROIDAL ILLNESS 
SYNDROME: 
 Low T4 and T3 with   normal or low TSH 
 Low concentration of thyroid hormones in all tissues 
 Found in  -   starvation, severe systemic illness, cardiac failure, liver 
Failure, infections, malignancy ,adrenal failure 
 Benefit of  thyroxine replacement is controversial 
 Treat the underlying illness. 
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ATYPICAL CLINICAL SITUATIONS 25: 
Struma ovarii : 
Ovarian teratoma with hyperfunctioning thyroid tissue. There is no 
thyroid enlargement. Diagnosed by body scan after radioiodine. 
 
Thyrotoxicosis factitia : 
Without thyroid enlargement, increased free T4 and lowTSH, depressed 
uptake in scintigraphy. To differentiate it from thyroditis, thyroglobulin level is 
done which is low. 
 
Choriocarcinoma of testes : 
Associated with thyrotoxicosis and gynaecomastia – measure HCG. 
 
Transient hyperthyroidism of Hyperemesis gravidarum: 
Increased beta HCG level is the most accepted mechanism. LH, FSH, 
TSH and beta HCG are glycoprotein hormones. They contain a specific beta 
subunit and a common alpha subunit. TSH level is decreased and serum free 
T4 raised. TFT returns to normal after recovery from hyperemesis gravidarum. 
Anti thyroid drugs need not be initiated. 
 
Trophoblast tumours : 
These tumours secrete HCG. This HCG is structurally similar to TSH  
and eventually stimulates thyroid. So there may be mild thyrotoxicosis. 
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AMIODARONE AND THYROID FUNCTION21: 
Amiodarone is a benzofuronic derivative with structural similarity with 
thyroxin. High concentration of iodine is present in amiodarone (39 % by 
weight). Daily optimal intake of iodine is around 150 – 200 micro gram. But 
with a dose of amiodarone between 200 – 700 mg per day, 7 – 21 mg of iodine 
enters the body. Half life of amiodarone is 52.6 ± 23.7 days. 
Thyroid function abnormality occurs in 50 % of patients on chronic 
amiodarone therapy. 
In areas with high iodine intake amiodarone induced hypothyroidism 
(AIH ) develops. Amiodarone induced thyrotoxicosis (AIT ) occurs in areas 
with low iodine intake. AIT develops even after several months of 
discontinuation of amiodarone due to its long half life.  Hypothyroidism is 
common in females and in patients with positive thyroid auto antibodies.  the 
thyroid function test should be done every 6 months in patients on amiodarone 
therapy. Thyrotoxicosis due to iodine excess is referred as AIT type I. 
Thyrotoxicosis due to toxic effect of amiodarone is called as AIT type II. 
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FEATURE AIT  TYPE   I AIT TYPE  II 
Etiology Iodine excess Thyroiditis 
Vascularity ( Doppler ) Normal /  increased Decreased 
Goiter Frequent Infrequent 
Thyroid antibodies Positive Negative 
Late hypothyroidism No Possible 
Thyroid Clinical signs Present Absent 
Serum IL 6 Normal Highly elevated 
Thyroglobulin Normal / mild elevation Highly elevated 
Radioiodine uptake Normal Decreased 
 
SUBCLINICAL HYPOTHYROIDISM: 
TSH level is raised but free thyroid hormones are normal. Indication for 
treatment of subclinical hypothyroidism is: 
1. TSH level > 10 
2. Thyroid auto antibodies positive 
3. Previous treatment of grave’s disease / radioiodine treatment 
4. Pregnancy. 
 
SUBCLINICAL HYPERTHYROIDISM: 
Undetectable TSH level and normal levels of T3 and T4. This may be 
endogenous when associated with nodular thyroid disease or underlying 
Grave’s disease and exogenous when over correction with levothyroxine. In 
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endogenous type, if patient is older ablative therapy with  I131is the best initial 
treatment. In exogenous type, dose of thyroxin has to be reduced except in 
those with prior thyroid malignancy in whom TSH suppression is mandatory. 
And if there is new onset cardiac failure, atrial fibrillation, angina, accelerated 
bone loss or borderline high serum T3 level is present, the dose of 
levothyroxine must be reduced. 
 
THYROID AND PREGNANCY: 
TBG level is increased during pregnancy. Total T3 and T4 levels may be 
raised but the free hormone levels are normal. Trimester adjusted reference 
values are to be taken as normal values during pregnancy. 
The free T4 index (“adjusted T4”) can be taken as a reliable assay 
during gestational period. The nonpregnant total T4 level (50–150 nmol/liter) 
can be taken by multiplying this range by 1.5-foldin the second and third 
trimesters of pregnancy. 
 
SCREENING FOR HYPOTHYROIDISM11: 
Various recommendations have been proposed. 
1. AmericanThyroid Association: 
Men and women >35 years must be screened every 5 years 
2. American association of clinical endocrinologist: 
Women and older people should be screened 
3. American college of obstetrics and gynaecology: 
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Women with autoimmune disease and family history of thyroid disease 
screened at 19 years 
4. American college of Physicians: 
Symptomatic thyroid disease in Women>50 years 
5. U.S Preventive services task force: 
No proper evidence for or against screening 
6. Royal College of Physicians: 
Healthy adult population is not justified 
7. Indian thyroid society: 
Routine screening is not indicated. 
 
SCREENING OF HIGH RISK POPULATION12: 
In this subset of patients routine screening for thyroid dysfunction would 
be beneficial 
1. Menstrual irregularities 
2. Infertility 
3. Dyslipidemia 
4. Unexplained hyponatremia 
5. Type 1 diabetes 
6. Carpel tunnel syndrome 
7. Depression 
8. Short stature 
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9. Recurrent abortion 
10. Down’s syndrome 
11. Pregnancy 
12. Family history of thyroid disease 
13. Exposure to radiation. 
 
DIAGNOSIS13: 
TSH estimation is a very effective method to screen thyroid dysfunction. 
IF TSH levels are elevated T3/T4 estimation should be done. If T3/T4 levels 
are normal possibility of subclinical hypothyroidism should be considered/ 
Free T3/T4 estimation maybe done to confirm the diagnosis. Anti TPO 
antibodies maybe done if Hashimoto thyroiditis is suspected. 
 
TREATMENT14: 
Treatment of all cases of subclinical hypothyroidism is not generally 
indicated. Follow up with repeat TSH levels may be required in some cases. 
There are three principal reasons for starting therapy in subclinical 
hypothyroidism 
1. To avert the symptoms of overt thyroid failure 
2. To reverse the effect of mild thyroid failure on various organ systems 
and relieve subtle signs and symptoms caused by mild thyroid failure 
3. In specific situations like: 
a. Positive anti thyroid antibodies 
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b.Dyslipidemia 
c. Pregnancy 
d. Infertility 
e. Goitre 
f. Obesity 
g. Carpel tunnel syndrome 
h. Menstrual irregularities 
i. Unexplained hyponatremia 
j. Short stature 
Whereas dosage of thyroxin of overt hypothyroidism is 1.6-
1.8μg/kg/day, an initial dose of thyroxin of up to 50-75μg per day is sufficient 
to bring the serum TSH level to normal in patients with subclinical 
hypothyroidism15. 
A lower dose (12.5-25μg daily)is given to coronary artery disease 
patients. After four to six weeks of therapy serum TSH is measured to see the 
response to treatment. It is also done after any change in the dose. Once the 
levels become stable, follow up TSH measurements are done annually. 
Thyroxine requirements increase pregnancy16 as there is a progressive thyroid 
failure and hence TSH has to be repeated at regular intervals and dose 
modified accordingly. 
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GOALS OF THERAPY: 
Goal should be to keep the patient’s thyroid profile in euthyroid range 
with optimum dose of thyroxin supplementation. TSH level should be kept in 
the range of 0.5 to 5.0μIU/ml. In the pregnant TSH should be <2.5μIU/ml. The 
patient should be followed up regularly till optimal control is achieved. 
If the patient had abnormal lipid profile before initiation of the treatment 
repeat lipid profile once in 3 months till the biochemical parameters 
normalizes. 
 
COMPLICATIONS OF THERAPY: 
1. Osteoporosis: Elderly, post-menopausal women are more prone to 
develop osteoporosis. This complication can be minimized by giving 
calcium supplements and encouraging calcium rich diet. 
2. Subclinical hyperthyroidism: This complication can be prevented by 
regular follow up and dose titration. Initially TSH should be repeated once 
in 6 weeks later once in 3 months. Once TSH levels stabilizes patient can 
be followed up once in 6 months and yearly thereafter. 
3. Overt manifestation of Ischemic heart disease: In those patients with 
established coronary artery disease is advisable to start with the lowest 
dose (12.5μ/day) followed by gradual titration according to TSH values. If 
high dose of thyroxin is initiated at the start of the therapy patient may 
present with ischemic symptoms. 
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HIV 
HISTORY: 
The origin of AIDS dates back to the late 1960s when scientists had no 
clue about this dreadful disease. A virus that affects the chimpanzees of Africa, 
known as the SIV (simian immunodeficiency virus) is very similar to the one 
causing AIDS in humans. It is believed that this deadly virus has spread from 
the remote parts of Africa to the rest of the world. The first case was reported 
among gay men known as GRID – gay related immunodeficiency33 in America 
in 1981. But later on an investigation of the blood of a bantu tribal man in 
Belgian Congo in 1959, who was identified to have a mysterious illness 
revealed the same virus. He was then declared as he first reported confirmed 
case of AIDS. 
Soon a large number of young people were identified with an illness 
characterised by a near total destruction of their immune system. Centre for 
Disease Control and Prevention (CDC) identified a large number of cases of 
pneumocystis carinii pneumonia and Kaposi sarcoma in the same year. This 
illness causing immunodeficiency and rare opportunistic infections was termed 
as Acquired Immuno Deficiency Syndrome (AIDS). In Pasteur Institute, 
France, Luc Montagnier isolated a virus from the lymph node of a patient in 
1983 and named it LAV (Lymphadenopathy Associated Virus)34.In 1984, Dr. 
Robert Gallo, isolated a virus which he called  HTLV- III in the  National 
Cancer Institute,  New York . Later both these viruses were found to be the 
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same. An antibody test to detect the virus called ELISA was developed in 
1985.  In 1986, the name of the virus was coined as the Human 
Immunodeficiency Virus (HIV) and the first drug ‘zidovudine’ was developed 
against HIV. 
“World AIDS Day” was first observed on December 1st 1988.  Deaths 
due to AIDS continued to multiply until the late 1990s. Then a newer treatment 
regimen was devised called HAART (Highly Active Anti Retroviral Therapy) 
and it revolutionised the entire treatment of AIDS.  More potent drugs  like 
Nevirapine  and  Saquinavir  were discovered which decreased the death rate 
to a great extent. 
 
GLOBAL AIDS CRISIS: 
AIDS continues to be the greatest challenge to modern medicine even 
today. 
AIDS statistics – WORLD 2013 
 No. of deaths due to HIV AIDS            :          1.7 million (approx) 
 No. of people living with HIV AIDS    :          35.5 million (approx) 
 No. of new infections with HIV            :           2.4 million (approx) 
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AIDS statistics – INDIA  2013 
 No. of deaths due to HIV AIDS             :            1.8 lakhs (approx.) 
 No. of new infections with HIV             :            1.04 lakhs (approx.) 
 No. of  people living with  HIV AIDS   :            24 lakhs (approx) 
 Prevalence of  HIV AIDS                      :             0.30% 
 
By the HAART regimen, the rate of  new infections has fallen by 33% , 
the  death rates have improved significantly but the number of PLHA (people 
living with HIV and AIDS)  is on the rise due to the increased longevity due to 
the  ART.  The rate of  spread and death toll continue to rise in sub Saharan 
Africa . 
The practical problems in reaching out to the AIDS victims are: 
 Unawareness  of  their  HIV status 
 Poor access to treatment due to it either lack of resources or lack of 
initiative 
 Low economic status of people of the developing nations 
 Social stigma25,26. 
Because of these inequalities ‘The AIDS pandemic’ has begun to plateau 
in some nations, while it is still on the rise in some others. 
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DEFINITION   AND   CLASSIFICATION24: 
DEFINITION: 
HIV positive person with T lymphocyte CD4+ count of <200 /µL has 
been termed as AIDS irrespective of associated infections or significant 
symptoms. 
 
CLASSIFICATION: 
The  current  CDC  classification  system  for HIV patients takes into 
account, the CD4+ T lymphocyte count and the associated clinical conditions. 
CD4+ T cell 
count (per µL) 
Category A – 
asymptomatic/ 
acute HIV/ PGL 
Category B – 
symptomatic 
Category C – 
AIDS indicators 
>500 A1 B1 C1 
200 – 400 A2 B2 C2 
<200 A3 B3 C3 
 
Once a patient  is designated category B as defined by his present 
clinical condition and CD4+ T cell count, it cannot be reverted back again to ‘ 
category A’ regardless of his recovery from the respective condition/ 
symptoms under category B. Similarly this applies to category C patients 
reverting back to category B. 
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CATEGORY A : 
Patients with one or more of the following conditions or symptoms, but 
conditions enumerated under category B or C must not be present. 
These include: 
 Generalised lymphadenopathy (persistent) 
 HIV infection– Asymptomatic 
 Acute symptomatic HIV infection  (clinical disease or history of acute 
HIV infection) 
 
CATEGORY B: 
Patients with one or more of the following conditions, but those under 
category C must not be present plus the conditions related to HIV or deficiency 
in cell mediated immunity. 
These include24: 
 Oral thrush 
 Oral hairy leukoplakia 
 >1 episode/ >1 dermatome – herpes zoster 
 Listeria infection 
 Fever/ diarrhoea> 1 month 
 Bacillary angiomatosis 
 Idiopathic thrombocytopenic pupura 
  
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 Vulvovaginal candidiasis  (non responsive to routine treatment/ 
recurrence) 
 Cervical dysplasia/ carcinoma in situ 
 PID like tubo ovarian mass or abscess 
 Peripheral neuropathy 
 
CATEGORY C: 
Diseases or infections coined together as AIDS defining illness24 
 Invasive candidiasis (esophagus, trachea, lung or bronchi) 
 Pulmonary or extrapulmonary TB 
 Histoplasmosis 
 Cryptococcosis 
 Chronic intestinal Cryptosporidiosis / isospora infection 
 CMV retinitis 
 Mycobacterium Avium Complex infection 
 Herpes simplex infections ( bronchitis, pneumonia, esophagitis) 
 Coccidioidomycosis 
 Pneumocystis carinii pneumonia 
 CNS toxoplasmosis 
 Recurrent pneumonia/ salmonella sepsis 
 Invasive cervical malignanacy 
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 Kaposi sarcoma 
 Primary CNS lymphoma 
 Burkitt s  lymphoma 
 HIV encephalopathy 
 AIDS cachexia 
 Progressive multifocal leukoencephalopathy (PML) 
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Figure 1 :THE AIDS VIRUS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scanning electron micrograph of HIV-1 virions infecting human CD4+ T 
lymphocyte 
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HUMAN IMMUNODEFICIENCY VIRUS - STRUCTURE: 
The human immune deficiency virus is classified under the family 
retroviridae and the sub family of lentiviruses. There are 2 types of viruses, 
HIV-1 and HIV-2. HIV- 1 is responsible for the widely spread global 
pandemic. Whereas HIV-2 isolated from western Africa is sporadic and its 
distribution is widespread. The virus has an icosahedral structure and has 2 
major envelope proteins, a surface protein gp 120 and another transmembrane 
protein, gp41.Being a retroviruses, HIV-1 has a single-stranded and a plus-
sense RNA. 
 
Figure 2: COMPONENTS OF HIV 
 
 
 
                                            HIV-1 - Structure including components 
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The reverse transcriptase enzyme also called as RNA-dependent DNA 
polymerase, is found within the virion core. This enzymereplicates the single-
stranded RNA of the virus to a double-stranded DNA intermediate. This viral 
DNA serves as the initiating precursor molecule needed for proviral 
integration, This takes place within the host cell genome. The core proteins of 
HIV-1 namely the capsid protein p24 and the matrix protein p18forms the 
major structure.  
A bilayered lipid covering which is a part of the host cell outer limiting 
membrane surrounds the viral core protein structures. During replication, it is 
from this membrane that the virus buds from the cell surface. The envelope 
glycoproteins gp120 and gp41 cover this outer membrane. These glycoproteins 
are encoded by virus-specific genes. The outer envelope proteins are 
responsible for cell adhesion and entry. 
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Figure 3:  LIFE CYCLE OF HIV 
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LIFE CYCLE OF HIV: 
The virus by means of its surface protein gp120 begins its replication 
cycle by binding to the CD4+ T lymphocyte. It undergoes conformational 
change after entering the cell with the help of gp120. Then it attaches with one 
of the major HIV co-receptors CCR5 and CXCR4. The binding of HIV to 
CD4+ T cell, by binding the gp120 to C type lectin receptor on their surface by 
the dendritic cells is known as DC – SIGN.  The penetration of the host cell 
membrane by the virion occurs with the help of the transmembrane protein 
gp41.  The pre- intergration complex which comprises of the viral RNA and 
viral enzymes is released into the host cytoplasm surrounded by a capsid 
protein coat 31. 
The target of the preintegration complex is the host cell nucleus. The 
RNA to DNA transcription is catalysed by viral reverse transcriptase 
enzyme. The resultant pro viral DNA is released from the nuclear capsid to 
enter the host nucleus. The enzyme integrase fuses the pro viral DNA with the 
host chromosome. The further course is variable. Either the provirus may now 
remain dormant or undergo different levels of genetic expression leading to 
production of large number of virions in the host. 
The host cell on activation initiates transcription of the integrated pro viral 
DNA into RNA or mRNA. 
The mRNA is modified by : 
 Cleavage 
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 Glycosylation 
 Phosphorylation 
 Myristoylation 
The assembly of the viral RNA, enzymes and proteins forms the entire 
virus particle. Lipid rafts are specialised areas of the host cell lipid membrane 
through which the virus buds out. The precursor proteins are cleaved by the 
viral enzyme protease to release the mature virion. 
Each step is regulated by viral regulatory gene products which can be 
targeted for therapeutic interventions. 
These include24 : 
 Virus – target cell binding 
 Virus – target cell fusion 
 Reverse transcriptase 
 Integrase 
 Protease. 
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Figure 4:MOLECULAR STRUCTURE OF HIV-1 
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GENOME AND ITS  DIVERSITY: 
There are numerous genes that code for functional and structural 
proteins. 
GENE FUNCTION 
Env Envelope glycoproteins 
pol Protease, reverse transcriptase and integrase 
enzymes 
tat, rev, nef, vif, vpr, 
vpu 
Regulates viral gene replication and host cell 
modification to enhance viral growth 
gag Core of virion (including p24 antigen) 
 
The  HIV 2  genome has vpx gene and lacks vpu gene which is present 
in  HIV 1. The cluster mutations occurring in the surface proteins accounts for 
the genomic diversity of HIV. The genomic reverse transcriptase is more or 
less conserved. These diversities lead to subclassifications into groups,  
subtypes  and  sub – subtypes . 
 
GROUPS24: 
 4 groups – group N, group M (major), group P and  group O (outlier), 
 Group M  is subclassified  into 9 different subtypes : A, B, C, D, F, G, 
H, J and K. 
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 Patients may be infected with more than one subtype which give rise to 
CRFs in combination (circulating recombinant forms). Examples include  
CRF02_AG  and  CRF01_AE 
 Subtype A and F are then sub classified into sub – sub – types like A1, 
A2 and F1, F2. 
 The geographic distribution of these different strains is widely 
distributed. Subtype C is the most prevalent strain all over the world. 
 Other common strains globally are CRF01_AE, CRF01_AG, A, B, C, 
D, and G. 
 There are numerous implications to this genetic diversity such as : 
1. Different rates of disease progression 
2. Varied response to therapy 
3. Development of resistance 
4. Continuous viral evolution 
5. Inability to produce vaccine against wide range of strains 
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GEOGRAPHIC DISTRIBUTION OF VARIOUS HIV STRAINS: 
1. India Subtype C 
2. China Subtypes B, C and 
BC recombinant forms 
3. Western Europe Subtype B 
3. Eastern Europe Subtype A,B and 
AB recombinant forms 
4. Sub-Saharan Africa Subtype C (most common) 
Subtype B and G, 
CRFO2_AG 
5. Australia Subtype B 
6. Southeast Asia CRF01_AE 
7. North America and some parts of South 
America 
Subtype B 
 
NEW EMERGING STRAINS: 
CRF35_AD Afghanistan and Iran* 
BF recombinant forms South America 
CRF14_BG Spain*   Portugal* 
Thai B.   Indian C. southern China* 
CRF03_AB Former soviet union 
*predominantly among injection drug users 
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MODES OF TRANSMISSION: 
Multiple ways of HIV transmission are: 
 Sexual contact 
 Vertical 
 Perinatal 
 Breast milk. 
 Blood and blood products 
No transmission has been reported through casual contact or insect bite. 
 
SEXUAL TRANSMISSION26,34: 
 May be homosexual or hetero sexual transmission 
 Higher rates of transmission with higher HIV RNA load 
 Increased risk  with unprotected anal intercourse (receptive) 
 Increased risk with genital infections ( as increased number of  
inflammatory cells are present) 
 Higher rate of transmission from male to female than vice versa 
 Increased risk with genital ulcers caused by Chlamydia, Trichomonas, 
Neisseria, Herpes etc. due to exposed mucous  membrane 
 Due to absence of  fore skin, male circumcision decreases risk of male 
transmission (decreased local concentration of  inflammatory  cells, 
decreased susceptibility to ulcerative infections, micro trauma) 
 Due to immature genital tract, adolescent girls are more susceptible to 
infection. 
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TRANSMISSION BY BODY FLUIDS26,27: 
 Screening of blood and blood products for presence of  HIV 
antibodies, HIV p24 antigen and HIV RNA is practiced in most 
countries 
 Transfusion related transmission cannot be completely avoided as HIV 
RNA levels cannot be detected in the first 10 – 15 days following 
infection due to undetectable levels of viremia, despite best technology 
 HIV transmission can occur through transfusions of whole blood, 
plasma, factor concentrates in haemophiliacs, leukocytes and platelet 
concentrates 
 No transmission occurs via hepatitis B Immunoglobulin, Rh 
immunoglobulin, hyper immune gamma globulin and plasma derived 
hepatitis B vaccine. 
 
TRANSMISSION IN INTRAVENOUS DRUG USERS: 
 Transmitted in injection drug abusers by sharing needles and drugs27. 
 Their sexual partners are also affected through homosexual or 
heterosexual transmission. 
 Their children are affected through perinatal transmission of HIV 
infection. 
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TRANSMISSION IN HEALTH CARE WORKERS26,27,28: 
Health care workers and laboratory personnels are at risk of procuring 
HIV infection from patients 
 Risk due to contact of infected blood with mucous membrane or 
breached skin by  needle stick injuries or cuts 
 Increase risk of transmission by contact  of  blood  with intact skin has 
not been documented 
 Other potentially infectious body fluids are: 
o Pleural 
o Peritoneal 
o Cerebrospinal 
o Pericardial 
o Semen 
o Vaginal secretions 
o Synovial 
o Amniotic fluids 
 No substantial risk of transmission: Saliva, sputum, sweat, feces, nasal 
secretions, vomitus, urine and tears. 
 Transmission increases with long contact, large volume blood contact 
and port of entry in debraded mucous membrane or breached skin. 
 Post exposure prophylaxis is warranted within 24 hours, in case of 
accidental exposure. 
 Universal precautions with specialized disposable kits should be used 
while handling infected individuals. 
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Figure 5: POST EXPOSURE PROPHYLAXIS 
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UNIVERSAL PRECAUTIONS: 
 Safe hand washing with soap and water 
 Disposable gloves 
 Protective long gowns 
 Protective eyewear/ goggles 
 Mask 
 Heat inactivation or chemical decontamination of reusable equipments 
 Blood spills- disinfection/ disposal 
 Impervious containers- sharps disposal 
 Caution of workers with raw area, denuded skin, active dermatitis etc. 
 
FETO – MATERNAL  TRANSMISSION34: 
 Maternal Transmission to fetus can occur antenatally, during 
labour or during breast feeding. 
 Higher risk of transmission are associated with : 
 Low maternal CD4 count 
 Pre term delivery 
 High maternal plasma viremia 
 Long duration between rupture of amniotic membrane  & 
delivery 
 Procedures like amniocentesis, amnioscopy, episiotomy etc. 
 Close match of maternal and fetal human leucocyte antigen 
 Chorioamnionitis/STD during pregnancy 
 Hard drug use/ cigarette smoking during pregnancy. 
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TRANSMISSION BY BREAST FEEDING: 
Transmission by breast milk is high during the early months of breast feeding 
 Risk is increased with : 
 Mastitis 
 Low maternal CD4 count 
 Detectable levels of HIV in breast milk 
 Maternal vitamin A deficiency 
 Risk of maternal transmission can be reduced by providing Zidovudine 
with or without lamivudine, to the mother in the last few weeks of 
gestation and to the fetus during the first week postnatally. 
 Perinatal transmission risk  is reduced by : 
 Anti retro viral prophylaxis antenatally 
 Reducing exposure of fetus to maternal blood and 
genital secretions (LSCS) 
 Universal voluntary testing / counselling of  all pregnant 
women 
 Avoiding breast feed in high risk cases 
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PATHOGENESIS OF HIV: 
HIV disease is a chronic infection which eventually leads to a 
quantitative and qualitative immunodeficiency because of ongoing immune 
destruction. Mechanisms by which this immune dysfunction is achieved  are: 
 Destruction of the immune cells by the replicating virus 
 Indirect effects like clearance of infected immune cells by the reticulo 
endothelial system 
 Excess immune activation leading to immune exhaustion 
 Activation induced apoptosis (cell death). 
The virus gains entry into the body by dendritic cells on the surface of 
mucosa or through microscopic rents in the mucosa. The virus then seeks its 
target -CD4+ T lymphocyte. The lymphocyte may be resting or activated. The 
activated T cells help in virus replication. It then spreads to the nearby draining 
lymph node where CD4 lymphocytes are available in large amounts. This 
causes an initial burst of viremia and wide dissemination of virus in primary 
infection leading to an early acute HIV syndrome24. 
Despite the massive immune response generated against acute viral 
infection, the virus is never eliminated from the human system and progresses 
to a chronic infection. The replication and immune destruction continues for 
almost 10years before the patient begins to deteriorate clinically. 
 
\ 
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PROTEINS THAT PLAY A VITAL ROLE IN PATHOGENESIS: 
CD4 Surface protein on T lymphocytes 
Gp 41 
Transmembrane protein helps to penetrate host membrane 
and coil upon itself thereby helping in fusion 
Gp120 
CD4 receptor ligand, numerous spikes over the envelope of  
the virion 
CCR5 
beta chemokine receptor for host cells like lymphocytes,  
dendritic cells, macrophages and glial cells 
CXCR4 Co receptor used by HIV  during late stages of infection 
 
FUSION: 
Gp120 of the virus gets attached to CD4 molecule which is found in T 
helper cells. Gp120 undergoes conformational change. This leads to exposure 
of another underlying protein Gp41 present beneath Gp120. It also causes 
binding to host cell through co-receptors CCR4/CXCR5. Gp41 penetrates the 
host membrane, succeeds in bringing together viral and cellular membrane 
resulting in fusion. 
 
FOUNDER VIRUS: 
All viruses of infected individual do not transmit disease. The virus 
during its replication in various lymphoid tissues acquires extreme genetic 
expression and diversity. So there is a high degree of variation in genetic 
characteristics and immunological response of existing virus in the plasma and 
the initial founder virus [17] 
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CHARACTERISTICS OF FOUNDER VIRUS: 
1. Minimal N-linked Glycosylation 
2. Limited genetic diversity 
3. Rapid divergence after transmission 
4. Presence of effective neutralizing antibodies in TP* 
5. Under representation in the plasma viremia of TP* 
6. Short V1-V2 loop 
*TP-Transmitting partner 
 
IMMUNE SYSTEM EVASION OF HIV24: 
The Human Immunodeficiency virus dodges all the defence mechanisms 
mounted against it and makes way for ambient survival conditions inside the 
host. Thus HIV infection is almost impossible to eradicate from the infected 
individual. 
The mechanism by which the virus evades the immune system includes: 
 Wide diversity of mutations and recombinations causing a sustained 
level of chronic viremia. 
 The Nef protein on the virus downregulates the HLA class I antigens on 
the virus affected cells and hence escapes immune recognition. 
 Mutant virus population that helps virus propagation by escaping 
recognition and destruction of the virus by CD8+ cytolytic cells. 
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 The neutralising antibodies are directed only against gp120 and gp41 of 
HIV because of: 
 Hypervariable regions in the genetic sequence of the 
envelope proteins. 
 post translational modification like glycosylation. 
 Conformational masking of antigenic epitopes. 
 Sequestration of the infected cells preferentially in the immune 
previledged sites like central nervous system to avoid detection. 
 Infection of virus specific CD4 cells selectively leading to elimination of 
virus specific immune response, with a profound damage to immune 
regulation and control of infection. 
 
VIRAL RESERVOIRS AND LATENCY: 
The wide range of infected cells in the dormant state in the body which 
act as a potential virus reservoir, is the greatest obstacle to eradication of HIV. 
These viral reservoirs exhibit pre – integration or post – intergration latency[24]. 
Pre – intergration latency is caused when the virus enters an inactive 
CD4 cell, and the reverse transcription is incomplete and the pro viral DNA is 
unable to immediately  intergrate into the host genome . This phase can last for 
hours to days. The pro viral DNA degenerates, if no host cell activation occurs 
within this period. 
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Post – intergration latency is caused when the virus enters into an active 
host CD4 cell and the pro viral DNA integrates into the host cell genome 
following which the host cell remains dormant but can replicate upon receiving 
an activation signal from cytokines. 
Reservoirs of HIV genome –exist in peripheral blood, lymph nodes, 
central nervous system and in other unidentified areas either active or in 
dormant form. Once the infection is established there is a progressive rise in 
the viral load and a progressive gradual decline in the CD4 cell count. This 
asymptomatic period is called clinical latency. It does not include microbial 
latency as there is continuous viral replication despite the absence of clinical 
features. 
 
 
 
 
 
 
 
 
 
 
 
58 
 
 
Figure 6:PATHOGENESIS 
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PATHOGENIC PROCESS IN LYMPHOID ORGANS: 
The major site for virus proliferation is the lymphoid organs. Rather than 
the plasma viremia, it is the true index of disease activity. After the initial 
infection the virus enters the lamina propria of the mucosa in the scattered 
lymphoid cells. It then replicates in the gut associated lymphoid tissue GALT. 
After that the virus undergoes amplification, replication and dissemination. 
Then the virus migrates to the draining lymph nodes where a greater 
concentration of lymphocytes is present which further promotes viral growth. 
This causes lymphadenopathy due cellular activation inside the lymph nodes 
which may be transient or generalised and persistent. Entry into the follicular 
dendritic cell is the next step which is found in the lymph node germinal 
center. These dendritic cells trap the intracellular and extracellular virions in its 
tender processes. These viruses persist in the lymph nodes for long duration 
and finally undergo a transition from acute to chronic persistent infection. 
The follicular dendritic cells, which are antigen presenting cells, present 
the viral antigens to the B lymphocyte. This triggers the production of 
antibodies and cytokines, which bring more immune cells leading to persistent 
immune activation. This inflammation leading to germinal centre hypertrophy 
and aiding continuous viral replication setting up a vicious cycle of immune 
activation and viral multiplication. 
Over time, the disease progresses to an advanced stage and the follicular 
dendritic cells are destroyed, with irreversible damage to the germinal centre 
due to collagen deposition. This leads to immune cell exhaustion and lymph 
nodes are burnt out, leading to profound immune deficiency ultimately[35]. 
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PATHOGENESIS DUE TO IMMUNE ACTIVATION: 
Immune activation and inflammation are the normal responses to any 
invading foreign antigen by the immune system. But in HIV infection , the 
aberrant immune response itself aids in viral replication and chronic persistent 
infection. Viral replication is most productive in activated immune cells. There 
are many factors that can produce immune activation and thus enhance the 
process of immune destruction by HIV. 
These are: 
 Co – infection with Epstein – Barr virus, parasite infestation, herpes, 
cytomegalovirus, tuberculosis and malaria. They accelerate the course of 
HIV infection. 
 HIV is associated with the process of enhanced apoptosis and it causes 
exacerbation of various autoimmune conditions like anti phospholipid 
antibody syndrome, idiopathic thrombocytopenic purpura,  Graves 
disease,  psoriasis etc. 
 Certain medical conditions which lead to persistent immune activation11: 
 Diabetes 
 Cardiovascular diseases 
 Liver disease (cirrhosis, hepatitis) 
 Accelerated aging syndromes 
 Dementias and other neurocognitive dysfunctions 
 Chronic kidney disease (any etiology) 
 Malignancies 
 Osteoporosis and other bone diseases. 
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CD4 DEPLETION: 
There is an enhanced lymphocyte turnover rate and destruction in HIV. 
The depletion of CD4 cells occur by various mechanisms[35]: 
DIRECT MECHANISMS 
 Gp120 self fusion with CD4 intracellularly 
 Interference with RNA processing 
 Formation of syncytia 
 Viral budding causing loss plasma of membrane intergrity 
 Accumulation of unintergrated pro viral DNA 
 
INDIRECT MECHANISMS 
 Enhanced apoptosis 
 Elimination of infected cells by virus specific immune   
responses. 
 Activation induced cell death 
 Inability to kill viral antigen coated cells 
 Decreased lymphocyte generation 
 Abnormal signalling pathways intracellularly 
 Autoimmunity. 
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IMMUNE RESPONSES : 
The primary HIV infection calls for a massive immune response 
including both  humoral and cell mediated immune systems : 
HUMORAL CELL MEDIATED 
 Enhancing antibodies  Inhibitory CD8+ T cells 
 Complement activation  Natural killer cells 
 Neutralising  antibodies  Cytolytic CD8+ T cells 
 Antibodies in antibody 
dependant cellular cytotoxicity 
 Antibodies in antibody 
dependant cellular cytotoxicity 
 Binding antibody  Inhibitory CD4+ T cells 
 
 
PROTEINS WITH ANTIVIRAL ACTIVITIES IN  HUMAN CELLS: 
1. APOBEC3G 
2. TRIM5α 
3. TETHERIN 
 
APOBEC3G: 
It acts on viral genome and substitute adenosine in the place of guanine 
in the viral genome. It causes suppression of viral transcription.  The virus 
overcomes its action by ubiquitinisation and degradration of the protein. This 
is carried out by vif gene of the virion19. 
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TRIM5α: 
This protein causes premature uncoating of viral nucleocapsid in cellular 
cytoplasm. This cellular antiviral mechanism is evaded by producing variation 
in capsid protein. 
 
TETHERIN: 
This is a newly discovered molecule present in the host cytoplasm called 
CD317. It inhibits budding of the formed virus through cellular membrane. 
Viruses are sequestered in tetherin mediated vesicles. Action of tetherin is 
inhibited by production of vpu protein by the virus. 
 
DIAGNOSIS OF HIV: 
      The initial diagnostic test of HIV is the antibody testing using Enzyme 
Immuno Assay. EIA is the screening test of choice due to its high sensitivity. 
The newer modalities provide a shorter window period of detecting the 
virus[11]. 
 Nucleic acid testing – 12 days 
 p24 antigen testing – 16 days 
 Antibody testing (EIA) – 22 days 
 Initial screening test for HIV is EIA. The test usually reads positive 
(highly reactive), indeterminate or negative (non – reactive). The test has high 
sensitivity index. Thus, when the test results are negative HIV may be ruled 
out. 
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Figure 7: ALGORITHM FOR DIAGNOSIS OF HIV 
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False positive reactions occur especially in pregnancy, transfusions, post 
transplantations, recent vaccinations, acute viral infections etc. 
If EIA is indeterminate, it should be repeated twice. If it is negative then 
HIV is ruled out. But if one test is positive, then a confirmatory test with 
western blot should be done. If it tests positive, then the patient is termed HIV 
positive. If the test is indeterminate even with western blot, repeat test should 
be done after 3 months.  
Other confirmatory test can be done like p24 antigen assay, HIV RNA 
assay, DNA PCR etc. All these tests are highly sensitive and can therefore can 
cause false positive results. Till date gold standard test would be EIA screening 
followed by confirmation with western blot. The other tests are used only 
when the conventional tests fail to provide confirmatory results24. 
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MONITORING DISEASE ACTIVITY: 
 The two parameters giving a reliable index of disease activity in 
monitoring patients with HIV infection are CD4+ T cell counts and HIV RNA 
level assay. These tests can performed at the disease onset and in regular 
periods thereafter. 
 The CDC guidelines recommend that ART is started when the CD4 
count is <500/µL. Drugs can be changed if the patient does not improve CD4 
counts by atleast 25%  after starting therapy. 
 Counts <200/µL - Pneumocystis jirovecii pneumonia prophylaxis started 
 Counts <50/µL - prophylaxis for MAC infections should be started 
HIV RNA levels indicate the level of viremia of the patient. It is be 
checked at the onset of the disease and at 3 – 4 months interval thereafter. 
Once anti retroviral therapy is started, RNA levels usually reduce to <50 
copies/ml within 6 months. After this the levels rise again and reach a new 
steady state. Monitoring is done every 4 weeks until the new steady state is 
reached and every 3 months thereafter24. 
 
CLINICAL FEATURES: 
HIV produces a clinical spectrum ranging from asymptomatic to 
advanced immunodeficiency called AIDS. Patient may either present with 
opportunistic infections or pathogenic manifestation of the virus per se36. 
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ACUTE HIV SYNDROME: 
 It develops after three to six weeks of infection in approximately half 
of the infected individuals. The symptoms are mostly self limiting and last 
only for few weeks. Due to acute reduction in CD4 counts, even opportunistic 
infections have been reported 24. 
Only one in ten infected patients will progress to fulminant disease. 
Sometimes patients deteriorate even after recovering from acute illness. 
Clinical manifestation during acute infection include : 
 
Systemic symptoms: 
 Headache 
 Myalgia 
 Vomiting 
 Fever 
 Lymphadenopathy 
 Nausea 
 Retro orbital pain 
 Arthralgia 
 Diarrhea 
 Pharyngitis 
 Malaise 
 Weight loss 
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Cutaneous manifestations: 
 Erythematous maculopapular Rash 
 Mucocutaneous ulcers 
 
Neurological manifestations[36]: 
 Peripheral neuropathy 
 Acute demyelinating Encephalomyelitis 
 Headache 
 Aseptic meningitis 
 Acute transverse myelitis 
 Encephalitis 
 
ASYMPTOMATIC STAGE: 
Symptoms of the patient disappear after the initial state of plasma 
viremia and acute HIV syndrome and there is recovery of immune function. 
There may be increase in the count of total CD8 cells24. 
But there is a steady decline in CD4 count. The count decreases by 
approximately 50 per year. Patient may be clinically silent even for a decade. 
But it is not microbiological or immunological latency. There is a continual 
destruction of immune system as well as progressive increase in viral load as 
the years advance even though patient is asymptomatic. 
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Figure 8: CLINICAL SPECTRUM WITH DECLINE IN CD4 COUNT 
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LONG TERM SURVIVORS: 
 Few patients remain asymptomatic even for a very long time. There are 
four such groups. 
1. LONG TERM NON PROGRESSORS (LTNPs): 
They are characterised by: 
 Prolonged asymptomatic period that may last for more than 
two decades. 
 Normal CD4 count. 
 Very low plasma viral load 
 Not on ARTs 
 
2. ELITE CONTROLLERS: 
These are special group of LTNPs. They are characterised by[24] 
 Normal CD4 count. 
 Strong immune response to virus 
 Extremely low plasma viral load 
 Over representation of HLA class I molecules. 
 
3. PATIENTS ON ART : 
The advent of the newer and effective HAART has revolutionized the 
treatment of AIDS on the face of the earth. When started early and  monitored 
ART confers a healthier, longer and better quality of life to these patients[25]. 
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4. ASYMPTOMATIC DECLINE: 
Fourth group includes patients who are asymptomatic despite the 
declining immunity. CD4 continues to decrease. They suddenly manifests with 
opportunistic infections and detoriate[24]. 
 
THE ACQUIRED IMMUNODEFICIENCY SYNDROME: 
Acquired immunodeficiency syndrome (AIDS) is defined in terms of 
either a CD4+ T cell count below 200 cells per µL or the occurrence of specific 
diseases in association with an HIV infection. In the absence of specific 
treatment, around half of people infected with HIV develop AIDS within ten 
years. The most common initial conditions that make us to suspect the onset of 
AIDS are esophageal candidiasis, Pneumocystis carinii pneumonia (40%) 
and HIV wasting syndrome/ cachexia (20%). Opportunistic infections, virus 
induced cancers, neurologic and psychiatric manifestation are the other 
common signs. 
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Figure 9: CLINICAL PICTURE OF AIDS 
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Figure 10: MECHANISM OF THE NATURAL HISTORY OF THE 
DISEASE 
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TREATMENT OF HIV: 
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HIGHLY ACTIVE ANTIRETROVIRAL THERAPY: 
 Early initiation of Highly active antiretroviral therapy (HAART) is the 
recent concept in the management of patients with HIV infection. 
 Overcomes resistant strains. 
 Combination of two NRTIs plus one or two PIs or a NNRTI. 
 Use of tenofovir and emtricitabine combined with efavirenz has the 
advantage of once daily dosing. 
 Decreases the viral load and cause long term suppression of HIV RNA 
below levels of detection. 
 Suppression of viremia and virus shedding in semen and vaginal 
secretions. 
 
BENEFITS OF HAART: 
 Fewer opportunistic infections and HIV-associated malignancies 
 Increased CD4+ T cell count 
 Prolonged survival 
 Restoration of lymph node architecture 
 Reduced immune activation 
 Clinical improvement 
 Ability to discontinue opportunistic infection prophylaxis and 
maintenance therapy. 
 
76 
 
SIDE EFFECTS OF HAART: 
 Hyperlipidemia 
 Lipoatrophy 
 Abnormal fat accumulation 
 Pancreatitis 
 Insulin resistance 
 Marrow suppression 
 Neuropathy 
 Hepatitis 
 Bone loss 
 Nephropathy 
 
 
 
 
 
 
 
 
 
 
 
77 
 
 
 
 
 
Figure 11: TARGETS FOR THERAPY 
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HIV ENDOCRINOPATHY AND METABOLIC DISORDERS: 
Various mechanisms play a role in developing endocrine and metabolic 
abnormalities in HIV patients. Most common ones are: 
 Secondary to opportunistic infections involving the gland 
 Direct effect of HIV infection on the gland and metabolism 
 Side effects of medication. 
They are: 
1. LIPODYSTROPHY: 
• 30 – 75 % of patients receiving ART 
• Increased total cholesterol, triglycerides, apolipoprotein B 
Hyperinsulinemia, hyperglycemia 
• Truncal obesity with peripheral wasting 
• 20% meet the criteria for metabolic syndrome 
• Common in regimens with protease inhibitors, stavudine and 
zidovudine 
• Treat with Gemfibrozil and Atorvastatin. 
 
2. OSTEONECROSIS OR AVASCULAR NECROSIS OF BONE: 
• On patients on ART, lipid lowering agents and steroids 
• Common in hip and shoulders 
• Diagnosed by MRI. 
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3. OSTEOPOROSIS: 
• 7% of women with HIV 
• 41% have osteopenia 
 
4. LACTIC ACIDOSIS: 
• Common with NRTIs and can be fatal 
 
5. SIADH: 
• Hyponatrenia 
• Associated with pulmonary or CNS disease 
 
6. ADRENAL INSUFFICIENCY: 
• Hyponatremia and hyperkalemia. 
• Due to mycobacterium infection, CMV, Cryptococcus, histoplasmosis 
or ketoconazole therapy. 
• Hyperkalemia also due to HIV nephropathy, trimethoprim and 
pentamidine. 
 
7. CUSHING’S SYNDROME: 
• Patients using local steroids like inhalers while taking Ritonavir. 
• Ritonavir inhibits CYP3A4 and prolongs the half life of steroids. 
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8. THYROID DYSFUNCTION: 
• Both hypo and hyperthyroidism 
• Most common is subclinical hypothyroidism 
• 10% of patients on ART have increased TSH 
• Opportunistic infections like pneumocystis jiroveci, CMV, toxoplasma 
may infect the gland causing non tender diffuse enlargement. 
 
9. GRAVES DISEASE: 
• Seen in immune reconstitution syndrome as a late complication. 
 
 
10. HYPOGONADISM: 
• 20-30% of men 
• Due to chronic illness, Ganciclovir therapy 
• Decreased libido, erectile dysfunction is also seen 
• Treat with androgen replacement therapy 
These endocrinopathies and metabolic disorders cause significant 
morbidity in HIV patients. It should be kept in mind and screened when they 
are suspected. 
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MATERIALS AND METHODS 
 
STUDY POPULATION: 
This study is to be conducted among 50 patients with Seropositive HIV, 
attending the Department of Medicine & ART Centre in Govt. Rajaji Hospital, 
Madurai. 
INCLUSION CRITERIA: 
• All HIV positive adult patients (Serology positive) attending ART 
Centre and also among in-patients of Department of Medicine, both 
sex. 
• Age > 18 years. 
 
EXCLUSION CRITERIA: 
• Known cases of thyroid disorder. 
• Patients on drugs altering thyroid hormone metabolism along with 
stavudine based anti-retroviral drugs. 
• All Diabetics. 
• Abnormal Liver function tests with SGOT/SGPT levels greater than 3 
times normal range, and Renal function tests abnormalities with serum 
Creatinine more than 1.6mg%. 
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DATA COLLECTION: 
• A Brief history with clinical examination will be done 
• Detailed Clinical Examination 
• HIV ELISA, CD4 Count 
• T3,T4,TSH 
 
LABORATORY INVESTIGATIONS: 
• 1. T3,T4,TSH 
• 2.CD4 Count 
 
STUDY PROTOCOL: 
In Patients of HIV Positive on ART, both sex, T3, T4, TSH, CD4 Count 
are done .Results are then analyzed. 
 
DESIGN OF STUDY: 
Prospective analytical study. 
 
PERIOD OF STUDY: 
JUNE 2014 TO SEPTEMBER 2014 
 
COLLABORATING DEPARTMENTS: 
 Department of Medicine 
 Department of Endocrinology 
 Regional ART Centre 
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ETHICAL CLEARANCE: 
Approval obtained from the institutional ethical committee, Madurai 
Medical College and Government Rajaji Hospital, Madurai. 
 
CONSENT: 
Individual written and informed consent. 
 
CONFLICT OF INTEREST: 
NIL 
 
FINANCIAL SUPPORT: 
NIL 
 
PARTICIPANTS: 
Patients of Govt. Rajaji Hospital, Madurai who fulfil the inclusion 
criteria. 
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STATISTICAL ANALYSIS: 
After obtaining the results, the data was compiled in a Microsoft Excel 
sheet. Statistical analysis was done using IBM SPSS Ver.20 (Statistical 
package for social sciences). Percentage prevalence, pvalues and standard 
deviation were calculated. The significance of relationship between groups was 
found out using Chi – Square test, logistic regression analysis and Student t 
test. 
 
LIMITATIONS OF STUDY: 
1.Small sample size. 
2.Lack of availability of Thyroid Antibodies at baseline. 
3.Role of single Antiretroviral drug has not been evaluated. 
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RESULTS AND ANALYSIS 
 
Table 1: Age distribution of patients studied 
 
Age in years Number of patients Percent 
20-30 17 34 
31-40 20 40 
41-50 9 18 
>51 4 8 
Total 50 100 
Comments :  Mean ± SD: 36.50±10.25 ; Maximum - 54  years ; 
Minimum - 20  years ; 
 
Figure 12 : Percentage distribution of the patients studied 
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Table 2: Gender distribution of patients studied 
 
Gender 
Number of 
patients 
Percent 
Male 28 56.0 
Female 22 44.0 
Total 50 100.0 
Comments:  About 56 % were males and 44 % were females. 
 
Figure13 : Gender  distribution of patients studied 
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Table 3: CD4 count distribution of patients studied 
 
CD4 count 
Number of 
patients 
Percent 
<100 7 14.0 
100-200 18 36.0 
200-500 16 32.0 
>500 9 18.0 
Total 50 100.0 
Comment : Mean ± SD: 311.46 ± 223.94 
 
Figure14 : Percentage distribution of the CD4 studied in the population 
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Table 4: Thyroid parameters of patients studied 
 
Thyroid Parameters No Of Patients (n=50 ) % 
T3   
<70 1 2.0 
70-190 47 94.0 
>190 2 4.0 
T4   
<5.0 10 20.0 
5.0-12.0 40 80.0 
>12.0 0 0.0 
TSH   
<0.5 0 0.0 
0.5-5.0 21 42.0 
>5.0 29 58.0 
 
 
 
 
89 
 
Figure15 : Percentage distribution of the thyroid profile studied 
 
 
 
Figure16 : Percentage distribution of the thyroid profile studied 
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Figure17: Percentage distribution of the thyroid profile studied 
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Table 5: Co relation of T3, T4 and TSH with CD4 count 
 
Variables 
CD4 Count 
< 100 (n=7) 100-200 (n=18) 201-500 (n=16) > 500 (n=9) Total (n=50) P' Value 
T3 89.00+26.81 112.56+20.28 128.31+17.83 107.2+6.42 113.34+22.35 0.056 NS 
T4 5.16+2.51 7.63+2.35 9.20+1.43 9.42+1.53 8.11+2.39 < 0.001** 
TSH 9.75+0.39 8.14+0.32 3.99+0.95 3.48+0.69 6.34+1.06 < 0.001 ** 
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Figure18: Co relation of T3 with CD4 count in the population studied in 
percentage 
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Figure19 : Co relation of T4 with CD4 count in the population studied in 
percentage 
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Figure20: Co relation of TSH with CD4 count in population studied (%) 
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Table 6: Co relation of BMI with CD4 count 
 
BMI(kg/m2) 
CD4 Count 
< 100 (n=7) 100-200 (n=18) 201-500 (n=16) > 500 (n=9) 
< 18.5 6(85.71%) 3(16.67%) 0(0) 0(0) 
18.5-24.9 1(14.28%) 15(83.33%) 11(68.75) 3(33.33) 
25-30 0(0) 0(0) 3(18.75) 6(66.67) 
> 30 0(0) 0(0) 2(12.5) 0(0) 
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Figure 21: Co relation of BMI with CD4 count 
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Table7: Correlation between HAART &T3, T4, & TSH 
 
ON HAART 
MEAN+S.D 
T3 
MEAN+S.D 
T4 
MEAN+S.D 
TSH 
YES 120.667+26.679 8.124+2.420 4.590+1.072 
NO 122.625+39.450 8.025+2.392 4.775+1.061 
P'VALUE 0.861 0.916 0.657 
 
 
Figure 22: Correlation between HAART &T3, T4, & TSH 
 
 
 
0.00
20.00
40.00
60.00
80.00
100.00
120.00
 T3  T4  TSH
114.41 
8.12 
4.59 
107.75 
8.03 4.77 
ON HAART 
YES NO
98 
 
DISCUSSION 
 
We have studied the thyroid profile of50 HIV infected individuals after 
considering the exclusion criteria. 
Out of the 50 individuals 34% were between 20-30 years of age and 
40% between 31-40years. Males constituted 56% and females were 44%, 
however in a study done by Palaniswamy et al had 50 individuals with 100% 
males8. 
The thyroid profile studies in these patients revealed majority of the T3 
and T4 values were in the normal range 70-190 (94%) and T4 5.0-12.0 (80%) 
however large portion of the TSH values were above normal range >5.0 (58%) 
(p=<0.001). 
In a study done by Marco Bongiviani et al20 on 35 HIV positive and 
Sonia Beltran et al5on 697 individuals showed results similar to that of ours 
where most of them were having a high TSH values but T3 and T4 were 
normal amongst these individuals. 
The CD4 count in our study had a wide range of spectrum from less than 
100 to more than500.When thyroid profile was co related with CD4 count it 
showed that people with higherCD4 count were having normal thyroid profile 
values than people with lower CD4 count. 
Jain G et al19 also showed that males and females were equally affected 
with subclinical hypothyroidism in HIV. 
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People with CD4 count between 100- 200 were having a mean TSH 
value of 8.45+/-0.32 and people with CD4 less than <100 were having TSH 
values 9.75+/-0.39 (p= <.001). 
When CD4 was co related in males and females it showed that both 
males and females were affected equally with p=<.001. 
A study done by Judie B alimonty21 also showed that both males and females 
were having sub clinical hypothyroidism in HIV. 
A low BMI was noted in individuals with a low CD4 count as compared 
to patients with higher CD4 counts. In a similar study done by Van Der Sande 
et al23showed that when a mean CD4 count of the population studied was taken 
mean CD4 of100 had BMI less than 18, mean CD4 of 160 had BMI of 16-
18and mean CD4 of 290 had BMI of 19-20 however normal BMI was seen in 
mean CD4 above 330. 
Marco Bongiviani study revealed increased prevalence of clinical 
hypothyroidism in both HIV individuals on HAART and those who were not 
on HAART20.Collazos et al16found a correlation between FT4 levels and CD4 
cell counts in patient treated with HAART. Majority of the patients had CD4 
count >200 cells/mm3.In our study, there is no significant correlation between 
thyroid dysfunction and patients on HAART. 
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CONCLUSIONS 
 
1. Thyroid dysfunction is found in significant association with HIV infection 
and a hypothyroid state occurs in HIV infection as the disease progresses. 
2. Males and females suffering from HIV show equal incidence of thyroid 
dysfunction. 
3. All individuals with CD4 count less than 200 should be screened for 
hypothyroidism. 
4. In individuals with a low CD4 count, a lower BMI is observed as 
compared to other patients with CD4 counts higher than them. 
5. There is no significant correlation between thyroid dysfunction and 
patients treated with HAART. 
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SUMMARY 
 
AIDS resulting from HIV infection may involve any organ system either  
directly or indirectly. Among them is the HIV related endocrinopathies that 
occurs during all stages of the disease, both early and late. In various studies, 
alterations in thyroid function tests has been analysed in HIV patients. Thyroid 
abnormalities are found to be more common in HIV infected patients and may 
be detectable even in the early phase of disease. 
The changes in thyroid function tests in PLHA patients can be attributed 
to HIV because the prevalence is higher than the compared normal population. 
However TFT cannot be used as a biochemical predictor of the progression of 
the disease in HIVinfectionas it does not have much popularity in India. In this 
study an entire spectrum of HIV+ patients are screened for thyroid 
abnormalities ranging from asymptomatic patients to full blown AIDS. 
The objective of the study was to correlate the thyroid function tests 
with the CD4 count in patients infected with human immunodeficiency virus 
(HIV) and to assess the course of thyroid dysfunction as the CD4 count further 
declined. 
It is a prospective study involving 50 HIV infected patients at various 
stages of the disease. Serum T3, T4, and thyroid stimulating hormone (TSH) 
was done in these patients. The results were analysed and thyroid function tests 
abnormalities were correlated with the CD4 count and analysed statistically. 
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The patients included in the study were interviewed and examined for thyroid 
abnormalities after obtaining an informed consent. 
Out of the 50 patients studied 56% were males and 44% were females. 
The age group ranged from 20 years to above 50 years of age. The CD4 count 
ranged formless than 100 to more than 500. It was seen that in 80% of the 
population had T4levels between 5-12.0 and 42% had TSH levels between 0.5 
to 5 whereas 48% of the studied population had an increased TSH above 5. It 
was seen that 100% of the patients with CD4 count less than 100 had an 
increased TSH of above 5 and 94% of the patients with CD4 between 100-200 
had TSH above 5. 
It was observed that HIV patients with a low CD4 count also had a low 
BMI when compared to the patients with higher CD4 count. In this study it is 
found that thyroid dysfunction has a significant association with HIV infection 
and a hypothyroid state occurs in HIV infection as the disease progresses. In 
this study we have noted that males and females suffering from HIV show 
equal incidence of thyroid dysfunction. Hence we have concluded that all 
individuals with CD4 count less than 200should be screened for 
hypothyroidism. 
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PROFORMA 
Name: 
Age/Sex/Occupation: 
Presenting complaints: 
H/o Fatigue, Constipation/ Diarrhoea, Cold/ Hot intolerance, Dry/ Moist skin, 
Hoarseness of voice, Weight gain/ loss, Menstrual disturbances, Palpitation etc. 
Past history: 
H/o Diabetes Mellitus, Systemic Hypertension, Drug intake altering Thyroid 
metabolism.  
Clinical examination: 
General examination: 
Consciousness, Pallor, jaundice, Clubbing, Lymphadenopathy, Periorbital 
puffiness, Pitting pedal edema, Dry skin, Slowed speech and movements, 
Examination of thyroid. 
Vitals: PR, BP, RR, SpO2, Temperature 
Systemic examination:  
CVS:    RS:    Abdomen:    CNS: 
 
LABORATORY INVESTIGATIONS: 
1. T3, T4, TSH 
2. CD4 Count  
 
 
 
 
 
 
 
 
 
 
 
 
 
                   MASTER CHART 
S.NO NAME AGE SEX BMI T3 T4 TSH CD4 RX 
NAIVE 
ON 
HAART 
1 KANNAN 22 M 26.1 110 6.4 2.7 684 NO YES 
2 PRAKASH 34 M 17.2 55 4.0 9.8 52 NO YES 
3 PETCHI 42 F 18.5 140 7.6 9.0 116 NO YES 
4 PANDI 52 M 30.2 112 7.1 3.5 420 NO YES 
5 RANGAN 27 M 23.7 118 9.2 5.2 238 NO YES 
6 RANI 31 F 18.7 120 11.2 8.4 132 NO YES 
7 VALLI 47 F 22.0 102 7.2 7.6 183 NO YES 
8 KALIMUTHU 25 M 24.2 108 10.5 3.5 700 NO YES 
9 MANICKAM 33 M 25.9 90 5.6 5.3 346 YES NO 
10 RAJA 41 M 17.8 92 4.2 9.6 82 NO YES 
11 GOWRI 25 F 18.1 140 7.9 7.4 176 NO YES 
12 SHANMUGAM 51 M 23.7 102 8.6 3.9 582 NO YES 
13 MOHAMMAD 28 M 26.2 141 9.2 4.2 346 NO YES 
14 PONNI 37 F 21.7 94 4.2 9.2 90 NO YES 
15 GANESAN 47 M 30.4 124 9.4 4.1 256 NO YES 
16 SEKAR 22 M 19.7 104 4.3 8.7 128 NO YES 
17 MAHARANI 31 F 19.4 118 10.4 5.2 290 NO YES 
18 PITCHAI 46 M 20.2 112 10.2 9.2 138 YES NO 
19 RASU 54 M 25.2 102 9.0 4.7 672 YES NO 
20 ARUN 20 M 19.8 134 9.1 4.3 348 NO YES 
21 TAMILSELVI 27 F 21.7 98 8.8 7.4 156 NO YES 
22 MURUGAYEE 38 F 18.4 80 3.8 9.4 86 NO YES 
23 SENTHIL 25 M 20.4 78 4.4 7.8 106 NO YES 
24 GOKILA 35 F 18 86 4.7 8.1 148 YES NO 
  
 
S.NO NAME AGE SEX BMI T3 T4 TSH CD4 RX 
NAIVE 
ON 
HAART 
25 MARUTHAM 32 F 24.2 98 11.1 7.4 170 NO YES 
26 KUMAR 39 M 25.7 110 10.9 4.0 502 NO YES 
27 RAVI 29 M 23.6 96 9.2 8.0 190 NO YES 
28 POONGODI 31 F 17.9 86 3.8 10.2 80 NO YES 
29 DHARMARAJ 46 M 26.6 102 8.5 3.8 800 NO YES 
30 NAGARAJ 51 M 24.5 116 7.9 3.5 378 NO YES 
31 SIVAPANDI 49 M 26.3 150 9.8 3.2 470 YES NO 
32 UMA 29 F 24.2 114 10.8 5.1 238 NO YES 
33 MALAR 31 F 20.9 126 10.1 4.6 270 NO YES 
34 ARUNACHALAM 35 M 23.2 132 9.5 3.0 418 NO YES 
35 VISVAM 32 M 21.7 122 11.2 2.9 582 NO YES 
36 KOTTAMMAL 26 F 19.9 146 7.1 7.6 120 NO YES 
37 RANJITHAM 37 F 21.8 154 8.3 2.7 432 NO YES 
38 JEYAM 39 M 18.2 112 3.9 7.7 116 NO  YES 
39 LALITHA 42 F 21.0 144 8.9 8.2 146 YES NO 
40 VIVEK 27 M 23.5 160 11.4 3.2 486 NO YES 
41 PRIYA 35 F 18.4 142 10.7 9.6 76 NO YES 
42 NANDHINI 31 F 20.4 138 9.5 2.4 320 NO YES 
43 ANTONY 44 M 22.3 114 8.7 9.6 132 NO YES 
44 PUNITHA 25 F 25.8 104 10.6 3.2 684 YES NO 
45 SABITHA 31 F 20.2 126 9.9 4.4 296 NO YES 
46 ANBU 39 M 20.5 94 4.7 10.2 110 NO YES 
47 BHARATHI 29 F 26.4 1O5 9.1 2.6 589 NO YES 
48 MANI 36 M 22.6 116 8.5 10.1 180 NO YES 
49 YALINI 23 F 21.4 126 8.9 4.2 144 NO YES 
50 SUBBIAH 21 M 17.5 74 5.4 10.5 45 YES NO 
                                 LIST OF ABBREVIATIONS 
  
 
HIV Human Immunodeficiency Virus 
AIDS 
 
Acquired Immunodeficiency Syndrome 
PLHA 
 
People Living With HIV and AIDS 
HAART Highly Active Antiretroviral Therapy 
PCP Pneumocystis carrnii Pneumonia 
OIs Opportunistic Infections 
FDA Food and Drug Administration 
CDC Centre for Disease Control 
WHO World Health Organisation 
ELISA Enzyme Linked Immunosorbent Assay 
HTLV Human T-Lymphotropic Virus 
CD4 
 
Cluster of Differentiation 4 
MHC Major Histocompatibility Complex 
CRF 
 
Circulating Recombinant Forms 
NACO National AIDS Control Organisation 
EBV Epstein barr virus 
 
Tg Thyroglobulin 
TSH Thyroid stimulating hormone 
NIS Sodium Iodide symporter 
WHO World health organization 
IQ Intelligence quotient 
MIT Mono iodotyrosine 
DIT Di iodotyrosine 
TPO Thyroid peroxidase 
G-PCR G protein coupled receptor 
TBG Thyroid binding globulin 
CMV 
 
Cytomegalovirus 
TFT Thyroid function test 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
  
 
 

 
